Tomato-made edible COVID-19 vaccine TOMAVAC induces neutralizing IgGs in the blood sera of mice and humans.

Autor:	Buriev ZT; Center of Genomics and Bioinformatics, Academy of Sciences of Uzbekistan, Tashkent, Uzbekistan., Shermatov SE; Center of Genomics and Bioinformatics, Academy of Sciences of Uzbekistan, Tashkent, Uzbekistan., Usmanov DE; Center of Genomics and Bioinformatics, Academy of Sciences of Uzbekistan, Tashkent, Uzbekistan., Mirzakhmedov MK; Center of Genomics and Bioinformatics, Academy of Sciences of Uzbekistan, Tashkent, Uzbekistan., Ubaydullaeva KA; Center of Genomics and Bioinformatics, Academy of Sciences of Uzbekistan, Tashkent, Uzbekistan., Kamburova VS; Center of Genomics and Bioinformatics, Academy of Sciences of Uzbekistan, Tashkent, Uzbekistan., Rakhmanov BK; Center of Genomics and Bioinformatics, Academy of Sciences of Uzbekistan, Tashkent, Uzbekistan., Ayubov MS; Center of Genomics and Bioinformatics, Academy of Sciences of Uzbekistan, Tashkent, Uzbekistan., Abdullaev AN; Center of Genomics and Bioinformatics, Academy of Sciences of Uzbekistan, Tashkent, Uzbekistan., Eshmurzaev JB; Center of Genomics and Bioinformatics, Academy of Sciences of Uzbekistan, Tashkent, Uzbekistan., Mamajonov BO; Center of Genomics and Bioinformatics, Academy of Sciences of Uzbekistan, Tashkent, Uzbekistan., Tulanov AA; Center of Genomics and Bioinformatics, Academy of Sciences of Uzbekistan, Tashkent, Uzbekistan., Ismailova AA; Institute of Immunology and Human Genomics, Academy of Sciences of Uzbekistan, Tashkent, Uzbekistan., Petrova TA; Institute of Immunology and Human Genomics, Academy of Sciences of Uzbekistan, Tashkent, Uzbekistan., Rozumbetov RJ; Institute of Immunology and Human Genomics, Academy of Sciences of Uzbekistan, Tashkent, Uzbekistan., Aripova TU; Institute of Immunology and Human Genomics, Academy of Sciences of Uzbekistan, Tashkent, Uzbekistan., Muminov MI; Center of Advanced Technologies, Ministry of Higher Education, Science and Innovations of Uzbekistan, Tashkent, Uzbekistan., Ermatova KY; Center of Advanced Technologies, Ministry of Higher Education, Science and Innovations of Uzbekistan, Tashkent, Uzbekistan., Dalimova DA; Center of Advanced Technologies, Ministry of Higher Education, Science and Innovations of Uzbekistan, Tashkent, Uzbekistan., Turdikulova SU; Center of Advanced Technologies, Ministry of Higher Education, Science and Innovations of Uzbekistan, Tashkent, Uzbekistan., Abdukarimov A; Center of Genomics and Bioinformatics, Academy of Sciences of Uzbekistan, Tashkent, Uzbekistan., Abdurakhmonov IY; Center of Genomics and Bioinformatics, Academy of Sciences of Uzbekistan, Tashkent, Uzbekistan.
Jazyk:	angličtina
Zdroj:	Frontiers in nutrition [Front Nutr] 2024 Jan 08; Vol. 10, pp. 1275307. Date of Electronic Publication: 2024 Jan 08 (Print Publication: 2023).
DOI:	10.3389/fnut.2023.1275307
Abstrakt:	Plant-based edible vaccines that provide two-layered protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outweigh the currently used parenteral types of vaccines, which predominantly cause a systemic immune response. Here, we engineered and selected a transgenic tomato genotype (TOMAVAC) that stably synthesized an antigenic S1 protein of SARS-CoV-2. Two-course spaced force-feeding of mice with ≈5.4 μg/ml TOMAVAC increased up to 16-fold the synthesis of RBD-specific NAbs in blood serum and the significant induction of S-IgA in intestinal lavage fluid. In a surrogate virus neutralization test, TOMAVAC-induced NAbs had 15-25% viral neutralizing activity. The results suggested early evidence of the immunogenicity and protectivity of TOMAVAC against the coronavirus disease 2019 (COVID-19) infection. Furthermore, we observed a positive trend of statistically significant 1.2-fold (average of +42.28 BAU/ml) weekly increase in NAbs in the volunteers' serum relative to the initial day. No severe side effects were observed, preliminarily supporting the safety of TOMAVAC. With the completion of future large-scale studies, higher-generation TOMAVAC should be a cost-effective, ecologically friendly, and widely applicable novel-generation COVID-19 vaccine, providing two-layered protection against SARS-CoV-2. Competing Interests: The study concept and results have been filed for patenting at the Intellectual Property Agency under the Ministry of Justice of the Republic of Uzbekistan with pending application no. IAP 2022 0247. (Copyright © 2024 Buriev, Shermatov, Usmanov, Mirzakhmedov, Ubaydullaeva, Kamburova, Rakhmanov, Ayubov, Abdullaev, Eshmurzaev, Mamajonov, Tulanov, Ismailova, Petrova, Rozumbetov, Aripova, Muminov, Ermatova, Dalimova, Turdikulova, Abdukarimov and Abdurakhmonov.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu